Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 2 · 28.6%High 0 · 0%

H2 receptor antagonists vs proton pump inhibitors

ICU mortality · people admitted to intensive care units

H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).

1 finding from 1 review

Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
RR 0.96 [0.78, 1.19]
12 studies · 1564 participants
Low

H2 receptor antagonists vs antacids

ICU mortality · people admitted to intensive care units

It is very uncertain whether H2 receptor antagonists changes all‐cause mortality in ICU compared with antacids (very low certainty).

1 finding from 1 review

Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
RR 1.01 [0.66, 1.55]
11 studies · 1321 participants
Very low

H2 receptor antagonists vs sucralfate

ICU mortality · people admitted to intensive care units

H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).

1 finding from 1 review

Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
RR 1.09 [0.95, 1.24]
21 studies · 3178 participants
Low

H2 receptor antagonists vs placebo or no prophylaxis

ICU mortality · people admitted to intensive care units

H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).

1 finding from 1 review

Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
RR 1.12 [0.88, 1.42]
14 studies · 1428 participants
Low

Endothelin receptor antagonists vs placebo

Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 0.78 [0.58, 1.07]
12 studies · 2889 participants
Low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
5 studies · 4207 participants
Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.9 [0.74, 1.11]
3 studies · 4070 participants
Moderate